| Acute treatment- cutaneous manifestations- moderate to severe erythema nodosum leprosum (ENL). |
| Not indicated as monotherapy - Presence of moderate to severe neuritis. |
| Maintenance therapy- cutaneous manifestations of ENL recurrence |
| DOSAGE AND ADMINISTRATION |
| 100 to 300 mg/day OD or in divided dose. |
| Initiate dosing at the low end of the dose range for less weighing patient. |
| Higher dosage range - severe cutaneous ENL reaction, or in those who have previously required higher doses to control the reaction (up to 400 mg/day) |
| Concomitant use of corticosteroids - moderate to severe neuritis. |
| Continue dosing at least 2 weeks. |
| Patients may then be reduced of medication in 50 mg decrements every 2 - 4 weeks. |
| Reduction should be attempted every 3 - 6 months and in reduction of 50 mg every 2 to 4 weeks. |
